In separate announcements, AstraZeneca Plc and Pfizer Inc said that trials of their respective treatments for prostate cancer, zibotentan and sunitinib malate, failed to show efficacy at Phase 3. Neither study threw up any unexpected safety issues. ---Subscribe to MedNous to access this article--- Company News
